TERNS PHARMACEUTICALS INC

Company Overview

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing internally discovered small-molecule therapeutics in oncology and metabolic disease, with lead programs TERN-701 (oral allosteric BCR-ABL inhibitor for CML) and TERN-601 (oral GLP‑1 receptor agonist for obesity). The company is R&D-centric (59 employees, no owned manufacturing, heavy reliance on CMOs and external clinical sites) and has a diversified pipeline that also includes TERN-501 and discovery-stage GIPR series, while having limited near‑term product revenue and dependence on licensing/partner milestones (e.g., Hansoh for Greater China). Recent financials show elevated R&D spend (R&D $70.1M of $101.9M operating expenses in 2024), net losses, a strong cash position after a $161.9M offering (cash ~$358M at year-end 2024; ~$315M at mid‑2025) and a stated runway into 2028 subject to clinical and financing risks.

Executive Compensation Practices

Compensation is likely weighted toward equity and long‑term incentives typical for the Biotechnology sector—base salaries plus significant stock‑based awards, options and performance/milestone‑linked pay—because management already disclosed higher stock‑based compensation tied to leadership transitions and program acceleration. Given the company’s R&D focus, key pay drivers will be program milestones (CARDINAL dose expansion and Q4 2025 readouts for TERN‑701, FALCON 12‑week data for TERN‑601), financing/cash management (successful offerings or collaborations), and partnering/licensing achievements (e.g., Greater China license milestones). Management’s disclosures show R&D spend rises on TERN‑701 and TERN‑601 and reduced spend on TERN‑501, so short‑term incentive/bonus design and equity vesting schedules may be tied to advancing those prioritized programs and preserving runway; severance/change‑in‑control protections and milestone bonus buckets are also common in this industry and likely here.

Insider Trading Considerations

As a clinical‑stage biotech in Healthcare/Biotechnology, insider trades will often cluster around non‑binary events: financing closings, licensing announcements, and the highly binary clinical data releases (Q4 2025 catalysts). Expect heightened insider selling following large equity financings or after public positive readouts, while open‑market insider purchases are rarer and often interpreted as strong signals; executives may use 10b5‑1 plans or observe formal blackout windows around trial readouts and regulatory filings. Regulatory factors—FDA/EMA accelerated pathways, orphan exclusivity, and the company’s emerging growth company election—make certain announcements materially price‑sensitive, increasing the likelihood of pre‑announcement trading restrictions; monitor SEC filings for Form 4 activity tied to the September 2024 offering, any post‑offering sales, and any 10b5‑1 or blackout disclosures around the upcoming CARDINAL and FALCON data.